The economics of prescription drugs
Download
1 / 38

The Economics of Prescription Drugs - PowerPoint PPT Presentation


  • 158 Views
  • Updated On :

The Economics of Prescription Drugs. Bio-Pharmaceuticals. New Chemical Entities (NCEs). Importance of Pharmaceuticals. Market Structure. Industry Concentration. Competition at Product Level. Within patent competition Generics after patent expiration

Related searches for The Economics of Prescription Drugs

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'The Economics of Prescription Drugs' - kele


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

Bio pharmaceuticals
Bio-Pharmaceuticals

  • New Chemical Entities (NCEs)



Market structure
Market Structure

  • Industry Concentration


Competition at product level
Competition at Product Level

  • Within patent competition

    • Generics after patent expiration

    • On patent competition from non patent friendly countries

  • Between patent competition

    • Me Too drugs and the “Gold mine” problem




Government regulation
Government Regulation

  • Regulation by the Food and Drug Administration (FDA)


Stages for a nce
Stages for a NCE

  • Discovery

  • Preclinical animal testing

  • File application for human testing

  • Phase I

  • Phase II

  • Long-term animal studies

  • Phase III

  • New drug approval


Liberalization of fda process
Liberalization of FDA Process

  • Generics

  • Orphan Drugs

  • Compassionate Use

  • User fee act of 1992

  • Requirement of Prescriptions (Rx)

  • Liberalization of Rx Req.


Cost benefit analysis of regulation
Cost Benefit Analysis of Regulation

  • Issues of agency, and who suffers the costs and benefits.


Cost benefit analysis of regulation1
Cost Benefit Analysis of Regulation

  • Effects of regulation on pharmaceuticals success in world markets


Demand for pharmaceuticals
Demand for Pharmaceuticals

  • Effects of increased insurance coverage for prescription drugs

  • Effects of direct marketing


Trends in promotional spending for prescription drugs 1996 2007
Trends in Promotional Spending for Prescription Drugs, 1996-2007

Promotional Spending ($ in billions)

NA

NA

NA

Total Spending:

$9.2

$11.0

$12.5

$13.9

$16.6

$19.1

$21.1

$24.2

$27.7

$11.4

$12.0

$10.4

Note: NA = Not Available. Numbers may not total due to rounding. Sampling is the value of samples left at sales visits to office-based physicians; the samples are valued at the prices at which they would be sold in retail pharmacies. Sampling data were not available for 2005 and 2006, so Total Spending numbers exclude amounts for Sampling. Detailing is expenses for the sales activities of pharmaceutical company representatives directed to office-based and hospital-based physicians and hospital directors of pharmacies; approximately 85% of detailing is for office-based sales visits. Direct-to-Consumer Advertising is expenses for advertising to consumers through television, magazines and newspapers, radio, and outdoors. Professional Journal Advertising is expenses for advertising appearing in medical journals.

Source: The Kaiser Family Foundation and the Sonderegger Research Center, Prescription Drug Trends, A Chartbook Update, November 2001, Exhibit 17, at http://www.kff.org/insurance/3161-index.cfm, updated by the Kaiser Family Foundation with data from the IMS Health website at http://www.imshealth.com (About Us, Press Room, 2007 Top-Line Industry Data, U.S.).


Talking to Doctors as a Result of Prescription Drug Ads, 2008

As a result of seeing an ad for an Rx drug, have you ever talked with a doctor about the specific medicine you saw or heard advertised, or not?

Among the 32% who have talked to a doctor as a result of seeing an Rx drug ad: Percent who said the doctor did one or more of the following…

Recommended you make lifestyle/ behavior changes

Recommended a different prescription

Gave you the prescription for the drug you asked about

No

Yes

Recommended an over the counter drug

Recommended any prescription drug

SOURCE: USA Today/Kaiser Family Foundation/Harvard School of Public Health: The Public On Prescription Drugs and Pharmaceutical Companies (conducted Jan. 3-23, 2008)


Pricing issues
Pricing Issues 2008

  • Pricing Differentials between brand name and generic drugs

  • Discounts to third party payers

  • Pharmacy benefits management firms

  • Price differences between countrues



Profitability of Pharmaceutical Manufacturers Compared to Other Industries, 1995-2006

Note: Percent is the median percent net profit after taxes as a percent of firm revenues for all firms in the industry.

Source: Kaiser Family Foundation and Sonderegger Research Center, Prescription Drug Trends: A Chartbook Update, November 2001, Exhibit 4.11, at http://www.kff.org/insurance/3161-index.cfm, updated with data from Fortune, Fortune 500 Industry Rankings: April 14, 2003, Vol. 147, No. 7, p. F-26; April 5, 2004, Vol. 149, No. 7, p. F-26; April 18, 2005, Vol. 151, No. 8, p. F-28; April 17, 2006, Vol. 153, No. 7, p. F-26; April 30, 2007, Vol. 155, No. 8, p. F-32.


International trade
International Trade Other Industries, 1995-2006

  • TRIPS (Trade Related Aspects of Intellectual Property Rights 1994)


American Public’s Views About Prescription Drugs Other Industries, 1995-2006

Upside

Downside

Do you think Rx drugs developed over the past 20 years have generally made the lives of people in the U.S…?

In general, do you think the price of Rx drugs is reasonable or unreasonable?

Better

Unreasonable

DK

Haven’t made much difference/DK

Worse

Reasonable

SOURCE: USA Today/Kaiser Family Foundation/Harvard School of Public Health: The Public On Prescription Drugs and Pharmaceutical Companies (conducted Jan. 3-23, 2008)


Serious Problems Paying, Not Filling Prescriptions and Skipping Rx Drug Doses Because of Cost, 2008

In past two years, have ever NOT filled a prescription because of the cost

In past two years, have skipped doses or cut pills in half to make Rx last longer

Say it is a serious problem for self/family to pay for Rx drugs you need

Percent who say yes to at least one of the above

SOURCE: USA Today/Kaiser Family Foundation/Harvard School of Public Health: The Public On Prescription Drugs and Pharmaceutical Companies (conducted Jan. 3-23, 2008)


Medicaid in the health system 2006
Medicaid in the Health System, 2006 Skipping Rx Drug Doses Because of Cost, 2008

Medicaid as a share of national health care spending:

Total

National Spending

(billions)

$2,106

$648

$660

$125

$217

NOTE: Does not include spending on SCHIP

SOURCE: Kaiser Commission on Medicaid and the Uninsured, based on A Catlin et al, “National Health Spending in 2006: A Year of Change for Prescription Drugs,” Health Affairs 27(1)14-29, January/February 2008. Based on National Health Care Expenditure Data, CMS, Office of the Actuary.


Problems Paying for Prescription Drugs, 2008 Skipping Rx Drug Doses Because of Cost, 2008

How much of a problem is it for you or your family to pay for prescription medicines that you need?

A serious problem

Not much of a problem

41%

A problem, but not serious

Source: USA Today/Kaiser Family Foundation/Harvard School of Public Health: The Public On Prescription Drugs and Pharmaceutical Companies (conducted Jan. 3-23, 2008).


Price (Manufacturer Price Increases) Skipping Rx Drug Doses Because of Cost, 2008

19%

Price (Manufacturer Price Increases)

25%

Utilization

(# of Prescriptions Dispensed)

42%

Utilization

(# of Prescriptions Dispensed)

47%

Types of Prescription Drugs Used

34%

Types of Prescription Drugs Used

34%

Relative Contributions of Utilization, Types of Prescription Drugs Used, and Price to Rising Prescription Drug Expenditures, 1993-1997 vs. 1997-2002

1993-1997

1997-2002

Source: Kaiser Family Foundation and Sonderegger Research Center analysis using National Health Expenditures data for prescription drugs from the Centers for Medicare and Medicaid Services, Office of the Actuary, National Health Statistics Group, at http://www.cms.gov/statistics/nhe/historical/, Table 2; price data from IMS Health, Pharmaceutical Pricing UPDATE, various years; and utilization data from IMS Health, National Prescription Audit Plus, various years, updated with data from the IMS Health web site at http://www.imshealth.com.


Percent of Seniors Who Did Not Fill or Delayed Filling Skipping Rx Drug Doses Because of Cost, 2008

Prescriptions Due to Cost, by Source of Drug Coverage, 2006

(Among Non-Institutionalized Seniors Taking 1 or More Rx)

NOTES: Did not fill or delayed filling prescriptions due to cost refers to within the past twelve months. VA is Department of Veterans Affairs. Reference group for statistical significance is Part D coverage (*p<0.05).

SOURCE: Kaiser/Commonwealth/Tufts-New England Medical Center National Survey of Seniors and Prescription Drugs, 2006.


6 drugs of the future
6 Drugs of the future Skipping Rx Drug Doses Because of Cost, 2008


Cancer Vaccine Skipping Rx Drug Doses Because of Cost, 2008


Male Birth Control Pill Skipping Rx Drug Doses Because of Cost, 2008


Anti-Addiction Pill Skipping Rx Drug Doses Because of Cost, 2008


Exercise Pill Skipping Rx Drug Doses Because of Cost, 2008


Anti aging pill
Anti-Aging Pill Skipping Rx Drug Doses Because of Cost, 2008


Smart Pill Skipping Rx Drug Doses Because of Cost, 2008


Pharma ads
Pharma Ads Skipping Rx Drug Doses Because of Cost, 2008


ad